Valuation dashboard for Biohaven Ltd. (BHVN) with P/E N/A, P/B 141.63, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that i...
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
Balance sheet quality for BHVN: current ratio of 3.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 141.63 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.60 |
| vs Current Price | -105.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BHVN | Biohaven Ltd. | $1.8B | 141.63 | ||
| VERA | Vera Therapeutics, Inc. | $2.4B | 5.93 | -84.1% | |
| CLDX | Celldex Therapeutics, Inc. | $2.6B | 4.25 | -52.4% | |
| IMNM | Immunome, Inc. | $2.3B | 5.06 | -50.6% | |
| PHVS | Pharvaris N.V. | $2.7B | 7.35 | -61.2% | |
| ABCL | AbCellera Biologics Inc. | $3.5B | 3.98 | -17.5% |
Price
| Price | $12.02 |
| Market Cap | $1.8B |
| Exchange | NYSE |
| Country | US |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABCL · CLDX · IMCR · IMNM · NTLA · PHVS · SION
Explore sector: Healthcare · Biotechnology
More sections of BHVN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks